Sonrotoclax-Azacitidine Trial Targets First-Line Higher-Risk MDS

A new ClinicalTrials.gov entry outlines a prospective, single-center phase 2/3 study testing sonrotoclax plus azacitidine in previously untreated higher-risk myelodysplastic syndromes. The study is built around a familiar clinical problem: patients with higher-risk disease often need therapy that can induce meaningful marrow responses without compounding the cytopenias and frailty already driven by the disorder itself.

The regimen uses 28-day cycles. Azacitidine is administered at 75 mg/m² subcutaneously or intravenously on days 1 through 7, while sonrotoclax is given orally on days 1 through 14. Cycle 1 includes a 4-day dose ramp-up for sonrotoclax, moving through 20 mg, 40 mg, 80 mg, and 160 mg before later cycles settle at the full target dose of 160 mg daily. In a disease where blast biology and apoptotic resistance are central obstacles, the combination is designed to push malignant progenitors toward cell death while preserving a practical outpatient backbone.

Why BCL-2 Inhibition Fits the Biology of Higher-Risk MDS

Higher-risk myelodysplastic syndromes sit at the edge of marrow failure and leukemic transformation. Abnormal clones survive by escaping normal apoptotic signaling, and BCL-2 blockade is meant to reverse that survival advantage. Sonrotoclax, a BCL-2 inhibitor, is being paired with azacitidine because hypomethylating therapy can alter the epigenetic program of diseased cells while the proapoptotic pressure from BCL-2 inhibition may deepen response.

This logic is clinically familiar in myeloid malignancies: one drug can make the clone more vulnerable, while the other forces the vulnerable clone over the threshold into apoptosis. In a syndrome defined by ineffective hematopoiesis, that dual pressure is attractive, especially when the goal is not simply temporary count improvement but a durable remission signal strong enough to change progression risk.

The trial’s primary endpoint is overall response rate, defined as the proportion of participants achieving complete response or partial response. Secondary outcomes extend the lens to complete remission rate, duration of response, progression-free survival, overall survival, and treatment-related hematologic and non-hematologic adverse events graded by CTCAE. Those measures reflect the central tension in higher-risk MDS drug development: a regimen must do more than stimulate a response label; it must hold that response long enough to matter for survival and marrow function.

Eligibility Criteria Keep the Cohort Clinically Focused

Enrollment is estimated at 10 adults, with no prior anti-tumor treatment for MDS, including hypomethylating agents or chemotherapy. Participants must meet WHO 2016 or 2022 diagnostic criteria based on bone marrow morphology, immunophenotyping, cytogenetics, and molecular testing. Risk enrichment is explicit: candidates must have higher-risk disease by any of several validated systems, including an IPSS-R score above 3.5, an IPSS score above 1, or an IPSS-M score above 0.

A few practical filters define the population further. Eligible patients need an ECOG performance status of 0 to 2, an expected survival time of at least 12 weeks, creatinine clearance of at least 50 mL/min, transaminases no more than 2.5 times the upper limit of normal, total bilirubin no more than 1.5 times the upper limit of normal, and left ventricular ejection fraction of at least 45%. Adults of all sexes are eligible, and written informed consent is required before any study procedures begin.

The exclusions are equally revealing. Acute promyelocytic leukemia is excluded, as are patients with prior BCL-2 inhibitor exposure, active uncontrolled infection, central nervous system involvement, severe uncontrolled cardiac disease, pregnancy, breastfeeding, or other conditions judged unsuitable by the investigator. Bone marrow dry tap and grade 2 to 3 myelofibrosis are also exclusion criteria, a reminder that very advanced marrow architecture can complicate both safety monitoring and response assessment.

Safety Will Matter as Much as Response

A BCL-2 inhibitor plus azacitidine is biologically appealing, but the regimen also enters a patient population already prone to anemia, neutropenia, thrombocytopenia, transfusion dependence, and infectious complications. In that context, hematologic toxicity is not a minor inconvenience; it is part of the therapeutic trade-off. If the combination suppresses the malignant clone without driving prolonged marrow aplasia, it could find a niche in first-line higher-risk MDS. If cytopenias deepen too far or infections accumulate, enthusiasm will narrow quickly.

The open-label, single-group design means the study will not answer comparative questions against azacitidine alone. It will, however, provide an early read on whether the regimen is tolerable in a carefully selected cohort and whether response rates warrant larger controlled testing. The estimated enrollment of 10 patients makes this an early signal-seeking effort rather than a definitive practice-changing trial.

Early Timing, Late Answers

Study start is estimated for September 2028, with primary completion also projected for September 2028 and final completion in December 2028. No results are posted yet. For now, the most important clinical detail is the direction of travel: investigators are trying to move BCL-2 inhibition into first-line higher-risk MDS, a setting where the unmet need remains substantial and where marrow biology may reward combinations that strike disease persistence from more than one angle.

The trial will also test an operational question at the bedside. Can an oral BCL-2 inhibitor, layered onto azacitidine, be delivered in an older and medically fragile population without pushing toxicity past the point where response loses its value? The answer will depend less on abstract mechanism than on whether remissions arrive with enough hematologic recovery, enough durability, and enough safety margin to justify moving this strategy beyond a ten-patient study.


Reporting by Dr. Revathy Mohan V.R., MBBS for Medicine World Foundation, with additional data provided by ClinicalTrials.gov.